{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:33:48Z","timestamp":1789205628315,"version":"build-2803163510"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Anti-CD38 monoclonal antibodies (mAbs) have significantly changed the multiple myeloma treatment landscape. This meta-analysis compared the efficacy and safety of anti-CD38 mAb-based therapy versus standard therapy in newly diagnosed multiple myeloma (NDMM) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a comprehensive literature search on PubMed, the Cochrane Database, and ClinicalTrials.gov. The primary outcomes were progression-free survival (PFS) and minimal residual disease (MRD) status. Dichotomous outcomes were pooled using risk ratio (RR) along with the 95% confidence interval (CI) in RevMan 5.4. Subgroup analysis and meta-regression analysis were performed. The RoB 2.0 tool was used to assess the risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Our meta-analysis included 11 randomized controlled trials. There were 5270 patients; 3040 TEs and 2230 TIEs. Anti-CD38 mAbs significantly improved MRD negativity (RR 1.94, 95% CI: 1.59\u20132.37;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.00001) and PFS (RR 0.51, 95% CI: 0.45\u20130.58;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.00001). Subgroup analyses revealed better outcomes for both the TE (MRD: RR 1.52, 95% CI: 1.37\u20131.68; PFS: RR 0.43, 95% CI: 0.34\u20130.54) and TIE (MRD: RR 3.49, 95% CI: 2.65\u20134.61; PFS: RR 0.55, 95% CI: 0.47\u20130.64) populations. Meta-regression revealed that Eastern Cooperative Oncology Group (ECOG) score 0 significantly influenced MRD status (\u03b2 = \u22120.015,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05), whereas ECOG scores 1 and 2 lacked statistical significance. Subgroup analysis revealed that PFS was significantly different between standard (RR 0.47) and high (RR 0.81) cytogenetic risk groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In NDMM patients, anti-CD38 mAb-based therapy significantly improved MRD status, and PFS compared with standard therapy alone, in both TE and TIE patients, suggesting a favorable benefit\u2013risk profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251314289","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T13:20:34Z","timestamp":1738156834000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-4264","authenticated-orcid":false,"given":"Muhammad","family":"Osama","sequence":"first","affiliation":[{"name":"Khyber Medical College Peshawar, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3250-2601","authenticated-orcid":false,"given":"Muhammad Haris","family":"Khan","sequence":"additional","affiliation":[{"name":"Saidu Medical College Swat, Swat, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4761-1914","authenticated-orcid":false,"given":"Safeena","family":"Khan","sequence":"additional","affiliation":[{"name":"Khyber Medical College Peshawar, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4018-4385","authenticated-orcid":false,"given":"Amna","family":"Hussain","sequence":"additional","affiliation":[{"name":"Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammara","family":"Tahir","sequence":"additional","affiliation":[{"name":"Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2703-1861","authenticated-orcid":false,"given":"Mehran","family":"Ullah","sequence":"additional","affiliation":[{"name":"Saidu Medical College Swat, Swat 19200, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Afridi","sequence":"additional","affiliation":[{"name":"Khyber Medical College Peshawar, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaid","family":"Ullah","sequence":"additional","affiliation":[{"name":"Kabir Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5515-1446","authenticated-orcid":false,"given":"Wajeeh Ur","family":"Rehman","sequence":"additional","affiliation":[{"name":"Saidu Medical College Swat, Swat, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X"},{"key":"e_1_3_4_3_2","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala SA","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel) 2021; 9: 3.","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.25306"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.012"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020265"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_4_16_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_4_18_2","unstructured":"Higgins J Thomas J. Cochrane handbook for systematic reviews of interventions. Version 6.5 https:\/\/training.cochrane.org\/handbook (2024 accessed 7 September 2024)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012539"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.02.009"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11507-9"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177546"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221106563"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04917-5"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041195"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.07.001"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010439"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac067"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112554"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162339"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13554"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0603"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01936-7"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166989"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251314289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251314289","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251314289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:34Z","timestamp":1777591054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251314289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":41,"alternative-id":["10.1177\/20406207251314289"],"URL":"https:\/\/doi.org\/10.1177\/20406207251314289","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"article-number":"20406207251314289"}}